Opdivo Plus Chemotherapy As Neoadjuvant Treatment In Resectable NSCLC Trial Hits Key Goal, Says BMY

Bristol Myers Squibb's (BMY) phase III study investigating its blockbuster drug Opdivo in combination with chemotherapy as *neoadjuvant treatment of resectable non-small cell lung cancer, dubbed CheckMate 816, has met the primary endpoint of pathologic complete response.

from RTT - Biotech https://ift.tt/33DseZF
via IFTTT